Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial

What Was Tested

This randomized controlled trial paper looks at Goserelin in the context of endometriosis.

This study is to investigate the effects of geserelin+tamoxifen (TAM) on estradiol level, breast density (BD), endometrial thickness (ET), and blood lipids in premenopausal and perimenopausal women with hormone receptor-positive early-stage breast cancer.

Who Took Part

According to the abstract, 110 patients were involved.

The age groups tagged for this paper are adults, women only.

This study recruited 110 premenopausal and perimenopausal patients with hormone receptor-positive early-stage breast cancer between 22 June 2008 and 31 December 2009 and randomly assigned them to receive either goserelin plus TAM or TAM alone for 1.5 years.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.

Blood levels of sex hormones and lipids and ET were determined at 0, 3, 6, 12, and 18 months.

Contralateral BD was also measured at 0, 12, and 18 months.

What Was Measured

The subject headings attached to it are Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, Endometrium, Estradiol, Goserelin and Lipids.

What This Means in Plain Language

The paper is a randomized study of Goserelin in 110 patients in people with endometriosis.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (British journal of cancer), a journal based in England.

More context: the Goserelin compound page, Endometriosis research.